Literature DB >> 20164446

Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma.

Zeshaan A Rasheed1, Jie Yang, Qiuju Wang, Jeanne Kowalski, Irwin Freed, Christopher Murter, Seung-Mo Hong, Jan-Bart Koorstra, N V Rajeshkumar, Xiaobing He, Michael Goggins, Christine Iacobuzio-Donahue, David M Berman, Daniel Laheru, Antonio Jimeno, Manuel Hidalgo, Anirban Maitra, William Matsui.   

Abstract

BACKGROUND: Specific populations of highly tumorigenic cells are thought to exist in many human tumors, including pancreatic adenocarcinoma. However, the clinical significance of these tumor-initiating (ie, cancer stem) cells remains unclear. Aldehyde dehydrogenase (ALDH) activity can identify tumor-initiating cells and normal stem cells from several human tissues. We examined the prognostic significance and functional features of ALDH expression in pancreatic adenocarcinoma.
METHODS: ALDH expression was analyzed by immunohistochemistry in 269 primary surgical specimens of pancreatic adenocarcinoma and examined for association with clinical outcomes and in paired primary tumors and metastatic lesions from eight pancreatic cancer patients who had participated in a rapid autopsy program. The clonogenic growth potential of ALDH-positive pancreatic adenocarcinoma cells was assessed in vitro by a colony formation assay and by tumor growth in immunodeficient mice (10-14 mice per group). Mesenchymal features of ALDH-positive pancreatic tumor cells were examined by using quantitative reverse transcription-polymerase chain reaction and an in vitro cell invasion assay. Gene expression levels and the invasive potential of ADLH-positive pancreatic cancer cells relative to the bulk cell population were examined by reverse transcription-polymerase chain reaction and an in vitro invasion assays, respectively. All statistical tests were two-sided.
RESULTS: ALDH-positive tumor cells were detected in 90 of the 269 primary surgical specimens, and their presence was associated with worse survival (median survival for patients with ALDH-positive vs ALDH-negative tumors: 14 vs 18 months, hazard ratio of death = 1.28, 95% confidence interval = 1.02 to 1.68, P = .05). Six (75%) of the eight patients with matched primary and metastatic tumor samples had ALDH-negative primary tumors, and in four (67%) of these six patients, the matched metastatic lesions (located in liver and lung) contained ALDH-positive cells. ALDH-positive cells were approximately five- to 11-fold more clonogenic in vitro and in vivo compared with unsorted or ALHD-negative cells, expressed genes consistent with a mesenchymal state, and had in vitro migratory and invasive potentials that were threefold greater than those of unsorted cells.
CONCLUSIONS: ALDH expression marks pancreatic cancer cells that have stem cell and mesenchymal features. The enhanced clonogenic growth and migratory properties of ALDH-positive pancreatic cancer cells suggest that they play a key role in the development of metastatic disease that negatively affects the overall survival of patients with pancreatic adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20164446      PMCID: PMC2831049          DOI: 10.1093/jnci/djp535

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  47 in total

1.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience.

Authors:  Jordan M Winter; John L Cameron; Kurtis A Campbell; Meghan A Arnold; David C Chang; Joann Coleman; Mary B Hodgin; Patricia K Sauter; Ralph H Hruban; Taylor S Riall; Richard D Schulick; Michael A Choti; Keith D Lillemoe; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

2.  An in vivo platform for translational drug development in pancreatic cancer.

Authors:  Belen Rubio-Viqueira; Antonio Jimeno; George Cusatis; Xianfeng Zhang; Christine Iacobuzio-Donahue; Collins Karikari; Chanjusn Shi; Kathleen Danenberg; Peter V Danenberg; Hidekazu Kuramochi; Koji Tanaka; Sharat Singh; Hossein Salimi-Moosavi; Nadia Bouraoud; Maria L Amador; Soner Altiok; Piotr Kulesza; Charles Yeo; Wells Messersmith; James Eshleman; Ralph H Hruban; Anirban Maitra; Manuel Hidalgo
Journal:  Clin Cancer Res       Date:  2006-08-01       Impact factor: 12.531

3.  Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity.

Authors:  R W Storms; A P Trujillo; J B Springer; L Shah; O M Colvin; S M Ludeman; C Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

4.  A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development.

Authors:  Antonio Jimeno; Georg Feldmann; Ana Suárez-Gauthier; Zeshaan Rasheed; Anna Solomon; Gang-Ming Zou; Belen Rubio-Viqueira; Elena García-García; Fernando López-Ríos; William Matsui; Anirban Maitra; Manuel Hidalgo
Journal:  Mol Cancer Ther       Date:  2009-01-27       Impact factor: 6.261

5.  Identification of pancreatic cancer stem cells.

Authors:  Chenwei Li; David G Heidt; Piero Dalerba; Charles F Burant; Lanjing Zhang; Volkan Adsay; Max Wicha; Michael F Clarke; Diane M Simeone
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

6.  Purification and characterization of mouse hematopoietic stem cells.

Authors:  G J Spangrude; S Heimfeld; I L Weissman
Journal:  Science       Date:  1988-07-01       Impact factor: 47.728

7.  Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations.

Authors:  Stephanie Ma; Kwok Wah Chan; Terence Kin-Wah Lee; Kwan Ho Tang; Jana Yim-Hung Wo; Bo-Jian Zheng; Xin-Yuan Guan
Journal:  Mol Cancer Res       Date:  2008-07       Impact factor: 5.852

8.  Stabilization of beta-catenin induces pancreas tumor formation.

Authors:  Patrick W Heiser; David A Cano; Limor Landsman; Grace E Kim; James G Kench; David S Klimstra; Maketo M Taketo; Andrew V Biankin; Matthias Hebrok
Journal:  Gastroenterology       Date:  2008-07-09       Impact factor: 22.682

9.  Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours.

Authors:  David M Berman; Sunil S Karhadkar; Anirban Maitra; Rocio Montes De Oca; Meg R Gerstenblith; Kimberly Briggs; Antony R Parker; Yutaka Shimada; James R Eshleman; D Neil Watkins; Philip A Beachy
Journal:  Nature       Date:  2003-09-14       Impact factor: 49.962

10.  Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy.

Authors:  Scott J Dylla; Lucia Beviglia; In-Kyung Park; Cecile Chartier; Janak Raval; Lucy Ngan; Kellie Pickell; Jorge Aguilar; Sasha Lazetic; Stephanie Smith-Berdan; Michael F Clarke; Tim Hoey; John Lewicki; Austin L Gurney
Journal:  PLoS One       Date:  2008-06-18       Impact factor: 3.240

View more
  195 in total

Review 1.  Targeting Hedgehog--a cancer stem cell pathway.

Authors:  Akil A Merchant; William Matsui
Journal:  Clin Cancer Res       Date:  2010-06-08       Impact factor: 12.531

Review 2.  Concise review: Cancer stem cells and minimal residual disease.

Authors:  Gabriel Ghiaur; Jonathan Gerber; Richard J Jones
Journal:  Stem Cells       Date:  2012-01       Impact factor: 6.277

3.  A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to Smoothened antagonists.

Authors:  Venugopal Chenna; Chaoxin Hu; Dipankar Pramanik; Blake T Aftab; Collins Karikari; Nathaniel R Campbell; Seung-Mo Hong; Ming Zhao; Michelle A Rudek; Saeed R Khan; Charles M Rudin; Anirban Maitra
Journal:  Mol Cancer Ther       Date:  2011-10-25       Impact factor: 6.261

Review 4.  Molecular biology of pancreatic ductal adenocarcinoma progression: aberrant activation of developmental pathways.

Authors:  Andrew D Rhim; Ben Z Stanger
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

Review 5.  The role of human aldehyde dehydrogenase in normal and cancer stem cells.

Authors:  Irene Ma; Alison L Allan
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

6.  Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival.

Authors:  Ines A Silva; Shoumei Bai; Karen McLean; Kun Yang; Kent Griffith; Dafydd Thomas; Christophe Ginestier; Carolyn Johnston; Angela Kueck; R Kevin Reynolds; Max S Wicha; Ronald J Buckanovich
Journal:  Cancer Res       Date:  2011-04-15       Impact factor: 12.701

7.  Aldehyde dehydrogenases in cancer stem cells: potential as therapeutic targets.

Authors:  David W Clark; Komaraiah Palle
Journal:  Ann Transl Med       Date:  2016-12

8.  Highly enriched CD133(+)CD44(+) stem-like cells with CD133(+)CD44(high) metastatic subset in HCT116 colon cancer cells.

Authors:  Ke-li Chen; Feng Pan; Heng Jiang; Jian-fang Chen; Li Pei; Fang-wei Xie; Hou-jie Liang
Journal:  Clin Exp Metastasis       Date:  2011-07-13       Impact factor: 5.150

9.  Double-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells.

Authors:  Xiaojun Yang; Xiaojuan Lin; Xiaomin Zhong; Sippy Kaur; Ning Li; Shun Liang; Heini Lassus; Liping Wang; Dionyssios Katsaros; Kathleen Montone; Xia Zhao; Youcheng Zhang; Ralf Bützow; George Coukos; Lin Zhang
Journal:  Cancer Res       Date:  2010-11-02       Impact factor: 12.701

Review 10.  Epithelial-to-mesenchymal transition in tumor progression.

Authors:  Elena Prieto-García; C Vanesa Díaz-García; Inmaculada García-Ruiz; M Teresa Agulló-Ortuño
Journal:  Med Oncol       Date:  2017-05-30       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.